Zydus Cadila gets USFDA nod for kidney stones tablets

Tags: Companies
Drug firm Zydus Cadila has received the final approval from the US health regulator to market Potassium Citrate ER tablets used in prevention of kidney stones.

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Potassium Citrate ER tablets in the strengths of 5 mEq, 10 mEq and 15 mEq, said the Zydus group's listed entity, Cadila Healthcare, said in a statement.

"The estimated sales in 2014 for Potassium Citrate ER tablets is $131.7 million, as per IMS," it added.

The group currently has 94 approvals and has so far filed 239 abbreviated new drug applications (ANDA), Cadila Healthcare said.

Shares of Cadila Healthcare were trading at Rs 1,098.95 per scrip in the afternoon trade on the BSE, up 0.35% from the previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • The current value of the rupee does not merit market intervention

    The rupee, losing 40 paise per month against the dollar since May, is expected to remain under pressure till the calendar runs out on December 31, bef

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Tushar Gandhi

Sustainable model for rural sanitation

Prime minister Narendra Modi has promised to build a toilet ...

Zehra Naqvi

How smells evoke strong memories

Remember that time when a passing fragrance transported you to ...

Dharmendra Khandal

Indian zoos need a fresh approach

Recently, when a man jumped in a tiger trench of ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture